720 related articles for article (PubMed ID: 31285550)
1. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
2. Thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance.
Yuan X; Yuan H; Zhang N; Liu T; Xu D
Clin Transl Med; 2022 Nov; 12(11):e1111. PubMed ID: 36394204
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation of the TERT promoter and its impact on human cancer.
Lee DD; Komosa M; Nunes NM; Tabori U
Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
[TBL] [Abstract][Full Text] [Related]
4. Occurrence, functionality and abundance of the TERT promoter mutations.
Rachakonda S; Hoheisel JD; Kumar R
Int J Cancer; 2021 Dec; 149(11):1852-1862. PubMed ID: 34313327
[TBL] [Abstract][Full Text] [Related]
5. Telomerase Biology Associations Offer Keys to Cancer and Aging Therapeutics.
Smith-Sonneborn J
Curr Aging Sci; 2020; 13(1):11-21. PubMed ID: 31544708
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E.
Song YS; Park YJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):515-525. PubMed ID: 32981294
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L; Stummer W; Senner V; Brokinkel B
Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
[TBL] [Abstract][Full Text] [Related]
8. Telomerase Reverse Transcriptase (TERT) in Action: Cross-Talking with Epigenetics.
Yuan X; Xu D
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284662
[TBL] [Abstract][Full Text] [Related]
9. Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.
Gocha ARS; Harris J; Groden J
Mutat Res; 2013; 743-744():142-150. PubMed ID: 23219603
[TBL] [Abstract][Full Text] [Related]
10. Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies.
Babizhayev MA; Yegorov YE
J Biomed Mater Res A; 2015 Dec; 103(12):3993-4023. PubMed ID: 26034007
[TBL] [Abstract][Full Text] [Related]
11. Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity.
Koh CM; Khattar E; Leow SC; Liu CY; Muller J; Ang WX; Li Y; Franzoso G; Li S; Guccione E; Tergaonkar V
J Clin Invest; 2015 May; 125(5):2109-22. PubMed ID: 25893605
[TBL] [Abstract][Full Text] [Related]
12. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
13. TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma.
Chun-On P; Hinchie AM; Beale HC; Gil Silva AA; Rush E; Sander C; Connelly CJ; Seynnaeve BKN; Kirkwood JM; Vaske OM; Greider CW; Alder JK
Science; 2022 Nov; 378(6620):664-668. PubMed ID: 36356143
[TBL] [Abstract][Full Text] [Related]
14. Crossroads of telomere biology and anticancer drug discovery.
Seimiya H
Cancer Sci; 2020 Sep; 111(9):3089-3099. PubMed ID: 32579791
[TBL] [Abstract][Full Text] [Related]
15. The regulations of telomerase reverse transcriptase (TERT) in cancer.
Liu M; Zhang Y; Jian Y; Gu L; Zhang D; Zhou H; Wang Y; Xu ZX
Cell Death Dis; 2024 Jan; 15(1):90. PubMed ID: 38278800
[TBL] [Abstract][Full Text] [Related]
16. Telomere Length Dynamics and the Evolution of Cancer Genome Architecture.
Cleal K; Norris K; Baird D
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29415479
[TBL] [Abstract][Full Text] [Related]
17. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
Zhao S; Wang F; Liu L
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
[TBL] [Abstract][Full Text] [Related]
18. Telomere length assessment and molecular characterization of TERT gene promoter in periampullary carcinomas.
Gregório C; Thakur S; Camara Rivero R; Márcia Dos Santos Machado S; Cuenin C; Carreira C; White V; Cree IA; Vukojevic K; Glavina Durdov M; Bersch Osvaldt A; Ashton-Prolla P; Herceg Z; Talukdar FR
Gene; 2023 Jul; 873():147460. PubMed ID: 37150235
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutations and telomeres during tumorigenesis.
Lorbeer FK; Hockemeyer D
Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
[TBL] [Abstract][Full Text] [Related]
20. Revisiting Telomere Shortening in Cancer.
Okamoto K; Seimiya H
Cells; 2019 Jan; 8(2):. PubMed ID: 30709063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
